In a report published Friday, Goldman Sachs Group initiated coverage on Biomed Realty Trust BMR with a Neutral rating and $20.00 price target.
Goldman Sachs noted, “BioMed owns a well-leased lab portfolio that currently generates strong cash flows. However, tenants representing 12% of rents have said that they will exit leases in the coming years; this helps to drive our well-below-average growth rate (projected 4.9% annual AFFO growth from 2013-2017 versus 8.3% for ARE). As with Alexandria, we assume a capex reserve in excess of the numbers that management reports. We estimate that BMR trades at 19.0X 2013E AFFO, a 12% discount to ARE and a 10% discount to the overall REIT sector, and at 15.7X 2017E AFFO, in line with ARE and at a 2% premium to the overall REIT sector.”
Biomed Realty Trust closed on Thursday at $20.12.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in